



PRESS RELEASE

Pharmaceutical industry welcomes the launch of Gavi's new investment round and AVMA

20 JUNE 2024, GENEVA – On 20 June in Paris, Gavi, the Vaccine Alliance, the Government of France and the African Union – together with Team Europe partners, co-hosted *The Global Forum for Vaccine Sovereignty and Innovation*.

The Forum launched Gavi's 2026–2030 Investment Opportunity (IO) to support its next replenishment – which will raise funds for immunisation in lower-income countries for Gavi's sixth strategic period, from 2026 through 2030 (Gavi 6.0).

The Forum also saw the launch of the African Vaccine Manufacturing Accelerator (AVMA), an innovative financial mechanism, designed by Gavi in close collaboration with Africa Centres for Disease Control and Prevention (Africa CDC), to help vaccine manufacturers in Africa to scale up production and foster regional diversification of vaccine manufacturing.

Commenting on the launch of Gavi, the Vaccine Alliance's 2026-2030 Investment Opportunity to support its next replenishment, Director General of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Dr. David Reddy, said:

"The pharmaceutical industry warmly welcomes the launch of Gavi's new investment round.

"For over two decades, IFPMA members have collaborated with Gavi to combat infectious diseases and tackle some of the biggest global health challenges.

"As founding partners of Gavi, we are proud of the contribution our member companies make, and we remain dedicated to accelerating the development, production, and equitable distribution of safe, effective, and affordable vaccines."

Commenting on the launch of the African Vaccine Manufacturing Accelerator (AVMA), Mr. Greg Perry, Assistant Director General, IFPMA said:

"The launch of the AVMA represents a groundbreaking financing instrument, to help both catalyze vaccine production within Africa and bolster global health resilience and equitable access to vaccines.

"For AVMA to have the maximum possible impact, it's paramount that we create the environment for the life sciences to thrive, including robust regulatory and legal frameworks, forecasting mechanisms, demand generation, and efficient procurement strategies.

“The pharmaceutical industry is committed to playing our part in the collective efforts to forge a sustainable vaccine ecosystem and delivering equitable access to innovative vaccines across the continent.”

Notes to the Editors

- IFPMA Global Health Progress Gavi webpage:
<https://globalhealthprogress.org/collaboration/gavi-the-vaccine-alliance/>
- IFPMA & DCVMN presentation illustrating the key stages and timeline to bring vaccines to the market: <https://globalhealthprogress.org/collaboration/gavi-the-vaccine-alliance/>

About IFPMA

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere.

For more information, visit ifpma.org.

For further information, please contact:

Elliot Dunster

Executive Director, Communications

+41 79 502 76 90

edunster@ifpma.org